JB Pharma acquires 4 pediatric brands from Dr Reddys
The acquisition has been done for a cash consideration of Rs 98.3 crores.
New Delhi: J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) has recently announced that the Board of Directors of the company has approved the acquisition of portfolio of brands, for use and exploitation within India, from Dr Reddy's Laboratories Limited.
JB Chemicals & Pharmaceuticals limited has entered into an agreement with Dr. Reddy's Laboratories Ltd. to acquire four of its brands "Z&D", "Pedicloryl", "Pecef" and "Ezinapi" for the India market.
All four brands are focused on the paediatric segment in the country with a total covered market size of 1800 crores as per IQVIA data. The combined sales of these brands as per internal estimates was INR ~33 crores for FY 2021-22.
The acquisition has been done for a cash consideration of Rs 98.3 crores. The acquisition shall be funded primarily through long term debt.
"JB Pharma sees good growth potential from the acquired brands as they are synergistic with its paediatric segment and will help it significantly leverage its field force strength," JB Pharma said in a BSE filing.
"The Acquisition shall be completed within next few working days," the company further said.
Founded in 1976, J.B. Chemicals & Pharmaceuticals Laboratories (JBCPL) is a pharmaceutical company headquartered in India. In India, the Company has five brands among the top 300 brands in the country. The Company exports its finished formulations to over 30 countries including the USA. It has seven state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for medicated lozenges. The manufacturing facilities are certified by leading regulators across the world.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.